Nestlé and Valbiotis have joined hands to develop TOTUM 63, a plant-based extract to reduce the chances of developing type 2 diabetes, announced a press release last week by Nestle Health Science. The deal comes just five years after creation of Valbiotis.
Majority of people suffering from diabetes have type 2 diabetes. It has been estimated by International diabetes federation that more than 400 million people were living with diabetes as of 2015 worldwide.
The new partnership formed will grant Nestlé global and exclusive rights to commercialize and use TOTUM 63 as a new nutritional therapy to combat the risk of diabetes. The deal was closed with a starting cost of 4.7 million euros with further payments of up to 62 million euros. Valbiotis will also enjoy eventual tiered royalties on net sales.
Hans-Juergen Woerle, the chief science and medical officer of NHSc, said that the research and development being conducted at Valbiotis is very promising. He further added, “We look forward to working together to realize the commercialization of TOTUM-63.”
The chief executive officer at Valbiotis, Sébastien Peltier, also commented that he saw Nestlé Health Science as an ideal and strategic partner to help commercialize this product worldwide and the company was “excited about the opportunity that this deal brings to Valbiotis and to the many millions of people around the world at risk of becoming type 2 diabetics”.
Nestlé Health Science (NHSc), is a subsidiary of Nestlé and was founded in 2011. The company aims to make available new nutritional therapies. Headquartered in Switzerland, the company aims to provide nutritional health solutions to its consumer through research and innovation. NHSc has invested heavily in nutritional research to cater to the holistic approach of modern medicine, and to work on preventive therapies.
Just last year, Valbiotis, a research and development company focused on fighting metabolic diseases, announced that TOTUM 63 (an active substance of VALEDIA), can significantly correct secretion of three hormones — glucagon, insulin, and GLP-1 — in a preclinical model of diabetes. The data was presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD). These three hormones are essential for blood glucose regulation in human body.
Insulin formed in pancreas helps human body to use glucose from carbohydrates and to store it for future use. The hormone keeps the blood sugar level from getting too low (hypoglycemia) or too high (hyperglycemia).
Glucagon, a catabolic hormone produced in pancreas, helps raise the concentration of glucose and fatty acids in the blood stream whereas Glucagon-like peptide 1 (GLP-1) works to help lower post-meal blood sugar levels in body.
TOTUM 63 is a combination of five plant extracts and is beneficial in lowering the risk of developing type 2 diabetes, as it targets several physio-pathological mechanisms of the disease.
The blend helps in reduction of insulin resistance, prevention of insulin secretion capacity, decrease in hepatic steatosis, reduction in inflammation of adipose tissue, and overall improvement of compositions and imbalances observed in preclinical diabetes.
Overall TOTUM 63 showed significant improvement in body weight and composition, the main parameters of carbohydrate metabolism, and a reduction in hepatic and blood triglyceride levels.